News
-
-
PRESS RELEASE
Telomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related Diseases
Telomir Pharmaceuticals announces in vitro findings showcasing Telomir-1's dual action targeting DNA methylation switches and the Wnt 'fuel line' driving cancer growth -
-
PRESS RELEASE
Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction
Telomir Pharmaceuticals, Inc. reveals new preclinical data showing Telomir-1's potent inhibition of histone demethylase enzymes implicated in cancer, autoimmune conditions, neurodegeneration, and metabolic disorders -
-
PRESS RELEASE
Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in A
Telomir Pharmaceuticals announces promising preclinical results showing the compound Telomir-1 restores mitochondrial function without triggering oxidative stress or cell proliferation in Progeria human cells -
-
PRESS RELEASE
Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin
Telomir-1 shows strong epigenetic effects in reversing STAT1 gene silencing, achieving greater efficacy than Paclitaxel and Rapamycin in aggressive prostate cancer models -
-
PRESS RELEASE
Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging
Telomir Pharmaceuticals, Inc. announces preclinical data showing lead candidate Telomir-1 prevents cellular aging in children with progeria. Study uses cell lines from Progeria Research Foundation
